Search results

Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death Vir and GSK plan to immediately seek Emergency Use Authorization in the U.S. and authorizations in other countries Additional new in vitro studies indicate VIR-7831 maintains activity against major circulating COVID-19 variants

Drug Candidate exerts strong SARS-CoV-2 specific antiviral properties in the in vitro infection test Preclinical data were published in the International Journal of Molecular Science MP1032 shows an outstanding safety profile in previous clinical trials  

A first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), Molecular Partners' DARPin therapeutic candidate for the potential treatment and prevention of COVID-19. MP0420 is designed to bind the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein at three distinct locations to prevent viral entry into cells. Preclinical data support

Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation Agency (Innosuisse) to investigate Mymetics’ intranasal Covid-19 vaccine candidates in preclinical studies.  This new study complements Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of M

Funds support clinical development of potent antibodies for the immunotherapy of COVID-19 and for BK virus infection in kidney transplant patients.

MP1032 exerts potent SARS-CoV-2 specific antiviral properties in Vero cells in-vitro infection assay MP1032 may reduce need for hospitalization and lethality after COVID-19 infection Data submitted to peer-reviewed journal

Molecular Partners (MP) and Novartis announced a collaboration agreement to develop, manufacture and commercialize MP’s anti-COVID-19 DARPin program, consisting of two drug candidates, MP0420 and MP0423. The collaboration aims to leverage MP’s proprietary DARPin technologies and Novartis’ broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to r

Vir Biotechnology, Inc. today announced the online publication of new research characterizing differences in antibody responses to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). This analysis, which is the largest to date, describes both the binding properties and kinetics of neutralizing antibodies, providing key insights that could be important to the development of new vaccines a

In April this year Mymetics has started a Covid-19 vaccine development project based on Mymetics’ virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. In May 2020 Mymetics and Baylor College of Medicine in Texas signed a Research Agreement to preclinically produce and test virosomes inc

Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.

15 min. audio presentation by Michael Altorfer, CEO Swiss Biotech Association, @Digital Bio, June 8-12, 2020

Mymetics (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that it has signed a Research Collaboration Agreement with Baylor College of Medicine for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combining them with Mymetics’ viro

Creoptix has a proven track record in biomolecular interactions and kinetic analysis in particular. By granting Prof. Aguzzi and his team from the University of Zurich access to their expertise and technology, they aim to find answers to the most pressing questions related to the immunological response of patients to SARS-CoV-2.

First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral “spike” protein with one drug candidate for broad inhibition of infection and mitigation of future drug resistance Initial testing performed in collaboration with the Swiss Federal Office for Civil Protection confirmed deep neutralization potential; candidate testing underway on live virus DARPin technology e

Samsung Biologics and Vir Biotechnology, Inc. today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir’s SARS-CoV-2 monoclonal antibody (mAb) program.

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks. Promising antibody candidate

Use our online form to provide feedback whether you look for support and partners, or whether you can provide solutions or assistance yourself. All news from Swiss biotechs on the fight against Covid.

Organizations working on new medications and vaccine formulations may request free safety testing using preclinical liver models that identify potential for toxic effects in humans.

Novochizol™  nanoparticle aerosol formulation can be used to deliver and confine any potential anti- COVID-19 drug to the lungs of acutely ill patients.

Vir Biotechnology, Inc. today announced that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19.

Help Memo Therapeutics AG to identify therapeutic monoclonal antibodies against SARS-CoV-2. If you were a Coronavirus patient and have overcome a heavy infection contact them. If you know such patients, please tell them to help in Memo Therapeutics "Hack Corona Initiative".